Australia's most trusted
source of pharma news
Posted 24 March 2026 AM
Australia faces a looming $90 billion-a-year obesity crisis without coordinated policy action – including ensuring access to new therapies - a Novo Nordisk commissioned report has found.
Conducted by The McKell Institute and Menzies Research Centre, the report titled A Preventable Crisis, warns that the economic cost of obesity will hit $87.7 billion a year by 2032 and $228 billion annually by 2060, with two-thirds of the costs linked to lost productivity, including absenteeism, reduced workplace performance and premature death.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.